Park Ha Biological Technology Co., Ltd. (BYAH) Stock Price & Analysis

Park Ha Biological Technology Co., Ltd. (BYAH) closed at USD 2.39 on Thursday, October 15, 2026, down 3.66% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 2.48; the Oct 15, 2026 session ranged USD 2.32–2.4 on volume of 4,571 shares. Market capitalization is $46.63M, with a 52-week range of USD 1.9–169.6 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.

Also available as compact Markdown for AI agents: nexqual.com/BYAH.md

Key facts (BYAH)

Analysts (BYAH)

Consensus None.

Total return (dividends reinvested) (BYAH)

1Y (from 2025-10-16)5Y (from 2024-12-23)
Total return-98.5%-99.8%
S&P 500 (SPY)+18.1%+85.1%
Per year-98.5%-97.3%
Volatility (annualized)161.8%293.0%
Max drawdown-98.6% (Oct 2025→Sep 2026)-100.0% (Jun 2025→Sep 2026)

Key Statistics (as of October 16, 2026 at 05:21 UTC)

PriceUSD 2.39
Change▼ 3.66% (down)
Previous CloseUSD 2.48
OpenUSD 2.36
Day RangeUSD 2.32 – 2.4
52-Week RangeUSD 1.9 – 169.6
Volume4,571 shares
Market Cap$46.63M
ExchangeNCM

Technical Analysis (BYAH)

Nexqual's technical model rates BYAH "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.

Overall SignalSTRONG SELL
RSI (14)44.96 (neutral)
vs SMA50Below (USD 2.68)
MACD-0.09 (negative)

Analyst Ratings (BYAH)

Wall Street analysts rate BYAH "None", per Nexqual as of October 16, 2026 at 05:21 UTC.

Consensus RatingNone

Earnings (BYAH)

Source: Nexqual, October 16, 2026 at 05:21 UTC.

Financials & Fundamentals (BYAH)

Total Revenue$2.54M
Revenue Growth (latest quarter, YoY)+1.50%
Gross Margin+94.90%
Operating Margin-76.53%
Profit Margin-214.17%
ROE-113.04%
Debt / Equity0.03
Current Ratio3.37
Total Cash$5.66M
Total Debt$186,331

Source: Nexqual, October 16, 2026 at 05:21 UTC.

Financial Health Score (BYAH)

Nexqual rates Park Ha Biological Technology Co., Ltd.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.

GrowthMixed — Revenue +1.5% YoY (latest Q), slow
ProfitabilityWeak — Not yet profitable — scaling phase
Balance SheetStrong — $6M cash, no debt
Cash FlowWeak — Operating cash flow -$273K (TTM)
EfficiencyCritical — ROE -113%, ROA -50.7%

Ownership (BYAH)

Insider Ownership+30.10%
Institutional Ownership+0.20%
Shares Outstanding19.46M
Float539,060
Short % of Float+0.11%

Source: Nexqual, October 16, 2026 at 05:21 UTC.

Leadership (BYAH)

Park Ha Biological Technology Co., Ltd. is led by Xiaoqiu Zhang (age 44), CEO & Chairman of the Board, per Nexqual as of October 16, 2026 at 05:21 UTC.

CEO & Chairman of the BoardXiaoqiu Zhang (age 44)
Chief Financial OfficerXiaoyan Zhu (age 47)
CTO & Product ManagerXinyu Li (age 39)

Major Backers & Investors (BYAH)

Notable institutional backers of Park Ha Biological Technology Co., Ltd. include Virtu Financial LLC, Morgan Stanley, according to Nexqual as of October 16, 2026 at 05:21 UTC.

Active Investors

InvestorStake
Virtu Financial LLC0.15%
Morgan Stanley0.14%

Source: Nexqual, October 16, 2026 at 05:21 UTC.

Peers & Related Stocks

SymbolNamePriceChange
MAGNMagnera CorporationUSD 11.25▲ 1.44%
HNSTThe Honest Company, Inc.USD 5.12▼ 1.35%
HELEHelen of Troy LimitedUSD 29.53▲ 6.15%
ODDODDITY Tech Ltd.USD 23.17▲ 4.75%
EPCEdgewell Personal Care CompanyUSD 28.1▼ 1.51%
SPBSpectrum Brands Holdings, Inc.USD 78.91▲ 2.24%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt